IN THE SENATE OF THE UNITED STATES
June 11, 2019
Ms. Hassan (for herself, Mr. Cassidy, Ms. Stabenow, Mr. Cornyn, Mr. Cardin, and Mr. Young) introduced the following bill; which was read twice and referred to the Committee on Finance
To amend title XIX of the Social Security Act to exclude authorized generic drugs from calculation of the average manufacturer price for purposes of the Medicaid drug rebate program, and for other purposes.
This Act may be cited as the
Fair and Accurate Medicaid Pricing Act of 2019 or the
Fair AMP Act.
Excluding authorized generic drugs from calculation of average manufacturer price under the Medicaid drug rebate program; excluding manufacturers from definition of wholesaler
Subparagraph (C) of section 1927(k)(1) of the Social Security Act (42 U.S.C. 1396r–8(k)(1)) is amended—
in the subparagraph heading, by striking
Inclusion and inserting
a new drug application and inserting
the manufacturer's new drug application; and
inclusive and inserting
Excluding manufacturers from definition of wholesaler
Section 1927(k)(11) of the Social Security Act (42 U.S.C. 1396r–8(k)(11)) is amended—
The amendments made by this section shall take effect on the first day of the first fiscal quarter that begins after the date of enactment of this Act.